UroGen and Senseonics Lead MedTech Growth as Commercial Transitions Take Hold
Key Takeaways
- UroGen Pharma and Senseonics reported strong Q4 2025 results, driven by the successful commercial launches of Zasturi and Eversense 365.
- Both companies are navigating critical transitions—UroGen through new reimbursement codes and Senseonics by assuming full commercial control—positioning them for significant revenue scaling in 2026.
Mentioned
Key Intelligence
Key Facts
- 1UroGen's Zasturi projected to reach $1 billion in peak revenue within four years.
- 2Senseonics full-year revenue grew 60% to $35.3 million following Eversense 365 launch.
- 3Cerus Corporation achieved record annual revenue of $233.8 million, up 16% year-over-year.
- 4RadNet's Digital Health segment revenue surged 48.2% to $27.9 million in Q4.
- 5UroGen's ENVISION trial for Zasturi showed an 80% complete response rate at three months.
- 6Senseonics 2026 revenue guidance set at $58 million to $62 million, implying up to 76% growth.
| Metric | |||
|---|---|---|---|
| 2025 Revenue | $109.8M (Combined) | $35.3M | $233.8M |
| Revenue Growth | N/A (Launch Year) | 60% | 16% |
| Key Product | Zasturi | Eversense 365 | Pathogen Reduction Kits |
| 2026 Guidance | $1B Peak Potential | $58M - $62M | $224M - $228M |
Who's Affected
Analysis
The fourth quarter of 2025 marked a pivotal shift for several mid-cap medical technology and biopharmaceutical firms, as the focus transitioned from clinical validation to aggressive commercial scaling. UroGen Pharma and Senseonics, in particular, demonstrated that the infrastructure for long-term growth is now firmly in place. For UroGen, the launch of Zasturi has been bolstered by the implementation of a permanent J code as of January 1, 2026, a regulatory milestone that significantly reduces reimbursement friction for providers. Senseonics similarly reached a corporate inflection point by assuming full commercial responsibility for its Eversense 365 product, moving away from its previous partnership with Ascensia Diabetes Care to capture the full value of its sales funnel.
UroGen’s commercial trajectory for Zasturi is underpinned by exceptionally strong clinical data from the ENVISION trial, which reported an 80% complete response rate at three months. Management’s projection of over $1 billion in peak revenue reflects a high degree of confidence in the drug's adoption curve, which is expected to reach its zenith within four years. The shift in the treatment landscape is already visible; while 60% of Zasturi utilization was hospital-based in 2025, the company reported a 50/50 split between hospital and community settings by February 2026. This diversification into community clinics is essential for reaching the broader patient population and is a direct result of the permanent J code, which provides the billing clarity necessary for smaller practices to stock and administer the therapy.
The company’s 2026 revenue guidance of $58 million to $62 million implies a continued growth rate of up to 76%, supported by a planned $12 million to $15 million investment in direct-to-consumer marketing.
Senseonics is mirroring this commercial evolution in the diabetes care space. The company reported a 60% year-over-year increase in full-year revenue, reaching $35.3 million. The doubling of the Eversense patient base in the U.S. and a 103% increase in new patient starts suggest that the 365-day continuous glucose monitoring (CGM) system is gaining significant traction against shorter-term competitors. By eliminating the revenue-sharing agreement with Ascensia, Senseonics is now positioned to retain higher margins on its growing sales. The company’s 2026 revenue guidance of $58 million to $62 million implies a continued growth rate of up to 76%, supported by a planned $12 million to $15 million investment in direct-to-consumer marketing.
What to Watch
Beyond the primary care and oncology sectors, Cerus Corporation and RadNet are demonstrating the value of specialized technological integration. Cerus achieved record annual revenue of $233.8 million, a 16% increase driven by strong demand for its pathogen reduction kits in the EMEA region. The company is currently navigating a transition from its INT 100 base to the more advanced INT 200 systems, while simultaneously eyeing a $30 million annual market opportunity in Germany. Meanwhile, RadNet is aggressively expanding its Digital Health segment, which saw a 48.2% revenue surge. The acquisition of Gleamer for up to €230 million is a strategic move to consolidate its position in AI-driven diagnostics, with management targeting $140 million in annual recurring revenue for the Digital Health division by the end of 2026.
Looking ahead, the biotech and medtech sectors are entering a phase where operational efficiency and market penetration will dictate valuation more than pipeline updates. For companies like UroGen and Senseonics, the challenge will be maintaining the momentum of their recent launches while managing the costs of expanded commercial footprints. Investors should closely monitor the repeat prescriber metrics for Zasturi and the expansion of the EON Care Group inserter network for Senseonics, as these will be the primary indicators of long-term market stickiness. As these firms move closer to break-even, the successful execution of their 2026 guidance will be critical in validating their independent commercial models.
How we covered this story
Every story in our biotech coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the biotech space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled biotech-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |